+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Alzheimers Diagnosis and Drugs Market - Growth, Trends And Forecast 2017 - 2022

  • ID: 4388398
  • Report
  • Region: Global
  • 205 pages
  • Mordor Intelligence
1 of 4
Alzheimer's disease is a progressive, degenerative disorder that attacks the brain's nerve cells, or neurons, resulting in loss of memory, thinking and language skills, and behavioral changes. According to our analysts, the global Alzheimer’s’ disease market is estimated to be approximately $10 billion for the year 2015. Due to drug patent expirations in 2017and many generics entering the market, it is expected to see a declination in the market growth by the year 2017. The market is anticipated to grow driven by the disease-modifying drugs, and the vast last-stage pipeline drugs. The prevalence of Alzheimer’s in the USA is almost 5 million and due to the increasing aging populations it is expected to grow further, also at the global level.

The major concern in the Alzheimers disease is detection of the condition in the patient.Blood biomarkers will help to detect the early onset of alzheimers whch would help in the treatment of the disease. Based on this, investment in the production of biomarkers is considered to be an advantage for the companies. Most of the pipeline drugs for Alzheimers’ fail in the late stage and there are only few drugs for this indication. Investing in the drug pipeline for Alzheimers is also beneficiary. There is a lack of surrogate markers for drug discovery and development. Development of surrogate markers will have definite effectiveness for the treatment of neurologic or psychiatric disease.

The market segmented by therapeutics which includes cholinesterase inhibitors, biomarkers and NMDA receptor anatagonists and by diagnostics which include brain imaging and blood tests.The major drugs in the Alzheimers market are Nameda, Aricept and Exelon and the expected decline of the market is due to patent expirations of Namenda and Aricept.

The major companies for therapeutics market are Roche, Novartis, Eisai and for diagnostics are GE Healthcare and Eli Lilly. AstraZeneca’s current research on a new drug for ALzheimers’ disease treatment, if succeeded, is estimate to be a market potential of $5 billion.

The Alzheimer’s disease market is further segmented by geographical region as North America which includes The USA and Canada, Latin American countries such as Brazil, Argentina, Colombia, European countries such as The UK, France, Germany, Italy, Asia-Pacific countries such as Japan, China, India and Australia and for Middle East & Africa countries are Saudi Arabia, UAE, Qatar and South Africa. The market of Asian countries may increase due to Edaravone, a promising drug for this indication .

This Report Offers:

Market Definition for the specified topic along with identification of key drivers and restraints for the market.
Market analysis for the Global Alzheimer’s Therapeutics and Diagnostics Market, with region specific assessments and competition analysis on a global and regional scale.
Identification of factors influencing the market scenarios, drug development and identification of key companies which can influence the market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.
Identification and analysis of the Macro and Micro factors that affect the Global Alzheimer’s market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1 Report Description
1.2 Markets Covered
1.3 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Definition
3.2 Alzheimers Disease Therapeutics Market (2017 - 2022)
3.3 Alzheimers Disease Diagnostics Market (2017 - 2022)
3.4 Market Drivers
3.4.1 Investment on Biomarkers for Drug Development
3.4.2 Increasing Pipeline Drug Development
3.4.3 Increasing Incidence and Prevalence of Alzheimers
3.4.4 Increasing sophisticated diagnostics for early detection and more precise drug development
3.4.5 Emerging Novel Diagnostics Technologies
3.5 Market Restraints
3.5.1 Early Diagnosis of the Indication is Challenging
3.5.2 Decrease in the market due to failures of late-stage drug
3.5.3 Lack of Surrogate Markers for Drug Discovery and Drug Development
3.5.4 Insufficient Research Funding and Lengthy, Expensive and Uncertain Process
3.6 Market Opportunitites
3.7 Market Threats
4. Market Segmentation
4.1 By Therapeutics
4.1.1 Cholinesterase Inhibitors
4.1.2 Biomarkers
4.1.3 NMDA Receptor Antagonists
4.2 By Diagnostics
4.2.1 Brain Imaging
4.2.2 Blood Tests
4.2 By Geography
4.2.1 North America The USA Canada
4.2.2 Europe The UK France Italy Germany Others
4.2.3 Asia Pacific Japan China India Australia Others
4.2.4 Latin America Brazil Argentina Colombia Others
4.2.5 Middle East & Africa UAE Saudi Arabia Qatar South Africa Others
5. Competitive Landscape
5.1 Mergers & Acquisitions
5.2 Agreements, Collaborations & Partnerships
5.3 Pipeline Product
5.4 Recommendations to new market players
6. Company Profiles
6.1 Therapeutics
6.1.1 Roche
6.1.2 Genentech
6.1.3 Novartis
6.1.4 Merck
6.1.5 Pfizer
6.1.6 Eisai
6.1.7 Bayer Pharmaceuticals
6.1.8 Pfizer
6.1.9 Daichi Sankyo
6.1.10 Biogen
6.2 Diagnostics
6.2.1 Eli Lilly
6.2.2 Amarantus Bioscience Holdings
6.2.3 GE Healthcare
6.2.4 Diagenic
6.2.5 Navidea
7. Appendix
7.1 Abbrevations
7.2 Sources
7.3 Disclaimer
Note: Product cover images may vary from those shown
3 of 4


4 of 4